AURA

Aura Biosciences, Inc. (AURA) Management Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Capital Allocation

Balance sheet remains very liquid with a current ratio of 16.8x and cash ratio of 3.47x, while debt is modest at 0.05x debt-to-equity.

However, profitability and cash generation remain weak, with negative free cash flow yield (-12.7%) and negative operating cash flow metrics.

Operational Discipline

Income quality is acceptable at 0.78, suggesting reported earnings are not heavily distorted relative to cash flow.

But operating returns remain deeply negative, with ROA at -37.6%, ROIC at -41.6%, and ROE at -73.2%.

Balance Sheet Management

Leverage is low, with debt-to-assets at 4.8% and debt-to-equity at 5.3%, which limits near-term solvency risk.

Net debt to EBITDA is only 0.39x, and working capital is positive at $309.5M.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aura Biosciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →